{"id":8657,"date":"2025-11-17T13:45:00","date_gmt":"2025-11-17T12:45:00","guid":{"rendered":"https:\/\/www.peptonicmedical.se\/?p=8657"},"modified":"2025-11-17T13:39:48","modified_gmt":"2025-11-17T12:39:48","slug":"correction-peptonic-medical-ab-publ-corporate-restructuring-continues","status":"publish","type":"post","link":"https:\/\/www.peptonicmedical.se\/en\/correction-peptonic-medical-ab-publ-corporate-restructuring-continues\/","title":{"rendered":"Correction: Peptonic Medical AB (publ) \u2013 Corporate Restructuring Continues"},"content":{"rendered":"\n<p><em>The press release announced today at 13:00 CET was referring to a previous press release that Uppsala District Court has approved the Company\u2019s request to extend its ongoing corporate reconstruction, the correct press release is that Svea Court of Appeal has rejected the Swedish Tax Agency\u2019s request to terminate the Company\u2019s corporate restructuring. Full press release below.<\/em><\/p>\n\n\n\n<p><strong>Peptonic Medical AB (publ) (\u201cthe Company\u201d) announces that today the Svea Court of Appeal has rejected the Swedish Tax Agency\u2019s request to terminate the Company\u2019s corporate restructuring. The Court of Appeal has thereby upheld the District Court\u2019s decision of 19 September 2025 to extend the Company\u2019s corporate restructuring under the Swedish Corporate Restructuring Act (2022:964) until 16 December 2025.<\/strong><\/p>\n\n\n\n<p><strong>For further information, please contact:<br><\/strong>Anna Linton, CEO, Peptonic Medical AB\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n\n\n\n<p>Email: <a href=\"mailto:anna.linton@peptonicmedical.se\">anna.linton@peptonicmedical.se<\/a>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n\n\n\n<p>Phone: +46 70-244 92 07<\/p>\n\n\n\n<p><strong>About Peptonic Medical AB\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n\n\n\n<p>PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women\u2019s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic\u2019s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.<\/p>\n\n\n\n<p>The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014<strong>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The press release announced today at 13:00 CET was referring to a previous press release that Uppsala District Court has approved the Company\u2019s request to extend its ongoing corporate reconstruction, the correct press release is that Svea Court of Appeal has rejected the Swedish Tax Agency\u2019s request to terminate the Company\u2019s corporate restructuring. Full press [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[19,3],"tags":[],"_links":{"self":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts\/8657"}],"collection":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/comments?post=8657"}],"version-history":[{"count":1,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts\/8657\/revisions"}],"predecessor-version":[{"id":8658,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/posts\/8657\/revisions\/8658"}],"wp:attachment":[{"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/media?parent=8657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/categories?post=8657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptonicmedical.se\/en\/wp-json\/wp\/v2\/tags?post=8657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}